- Motley Fool•10 hours ago
PCSK-9 inhibitors lowered LDL-C by roughly 60% in clinical trials, but do their costs far outweigh their benefits?
- Investor's Business Daily•yesterday
Week in review: Fed chief Janet Yellen said the rate hike case is stronger. Mylan's EpiPen price hike outrage roiled drug stocks. Best Buy soared as dollar stores dived.
- Market Realist•yesterday
According to a Bloomberg consensus of 19 brokerage firms as of August 23, 2016, 94.7% of analysts recommend a "buy" for BioMarin stock.
NYSE - NYSE Real Time Price. Currency in USD
|Bid||38.60 x 400|
|Ask||38.92 x 100|
|Day's Range||38.51 - 39.21|
|52wk Range||37.41 - 51.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.26|
|Avg Vol (3m)||2,327,220|
|Dividend & Yield||1.66 (4.33%)|